Navigation Links
Hospira Reports Third-Quarter 2009 Results
Date:10/27/2009

ge. Depreciation and amortization is now expected to be between $225 million and $235 million. Capital expenditures are projected to be between $155 million and $175 million.

*Use of Non-GAAP Adjusted Financial Measures

Non-GAAP financial measures used in this press release are reconciled to the most comparable measures calculated in accordance with GAAP in the schedules attached to this release.

Webcast

Hospira will hold a conference call for investors and media at 8 a.m. Central time on Tuesday, Oct. 27, 2009. A live webcast of the conference call will be available on Hospira's Web site at www.hospirainvestor.com. Listeners should log on approximately 10 minutes in advance to ensure proper setup for receiving the webcast. A replay will be available on the Hospira Web site for 30 days following the call.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.

                 Private Securities Litigation Reform Act of 1995 --
                   A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including projections of certain measures of Hospira's results of operations, projections of certain charges and expenses, and other statements regarding Hospira's go
'/>"/>

SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
2. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
3. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
4. Hospira to Present at Credit Suisse 18th Annual Healthcare Conference Nov. 11
5. Hospira Names Daphne E. Jones Chief Information Officer
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... relief targets that could be used to provide ... College London made the discovery when researching how ... the body. , Dr Marzia Malcangio said: "We ... generation and our findings could help chemotherapy patients ... potential side effect of some chemotherapy drugs (such ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2
... Association (NMA), the nation,s premier membership organization for ... amount of $120,000 from the W.K. Kellogg Foundation. ... grant commitment, designed "to promote health care coverage ... partner organizations."Partner organizations for this effort include Families ...
... in urban areas , , TUESDAY, April 21 (HealthDay News) -- ... areas are not less likely to get a kidney transplant ... , Researchers analyzed U.S. data on 699,751 adults with kidney ... 1995 and 2007. After about two years on the list, ...
... reduced risk of relapse or death, study finds , , ... lymphoma who drank wine before their diagnosis appeared to ... to a study that,s the first to identify this ... women with non-Hodgkin lymphoma and found that, overall, those ...
... your memory will get worse as you get older may ... University have found that senior citizens who think older people ... worse than seniors who do not buy in to negative ... published earlier this month, psychology professor Dr. Tom Hess and ...
... April 21 DaVita Inc. (NYSE: ... services for those diagnosed with chronic kidney disease ... as the company,s Senior Vice President of Federal ... public policy efforts in Washington, D.C. and report ...
... quality care needs in skilled nursing facilitiesCOLUMBUS, Ohio, ... Nursing Care Coalition, the umbrella group representing Ohio,s ... of the state budget bill unveiled by House ... services to Ohio,s frail elderly and disabled citizens ...
Cached Medicine News:Health News:National Medical Association Receives Funding From Kellogg for Training Community Advocates 2Health News:Distance No Bar to Kidney Transplants in Remote Areas 2Health News:Wine May Guard Against Lymphoma Recurrence 2Health News:Think memory worsens with age? Then yours probably will 2Health News:John Schaeffler Appointed Senior Vice President for Federal Legislative Affairs 2Health News:Skilled Nursing Care Coalition Praises House Leadership for Budget Changes 2
For the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma....
For the quantitative in vitro determination of Carbamazepine in human serum...
For the quantitative in vitro determination of Phenobarbital in human serum....
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Medicine Products: